The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease

blonca9
Sep 4, 2024
1 min read

Samir Ounzain explains the way HAYA studies how long non-coding RNAs, a once poorly understood component of the genome, affects disease and then targets it with therapeutics.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight